A detailed history of High Tower Advisors, LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, High Tower Advisors, LLC holds 506,347 shares of EXAS stock, worth $25.1 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares
506,347
Previous 507,396 0.21%
Holding current value
$25.1 Million
Previous $21.4 Million 60.83%
% of portfolio
0.05%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$42.43 - $70.83 $44,509 - $74,300
-1,049 Reduced 0.21%
506,347 $34.5 Million
Q2 2024

Aug 13, 2024

SELL
$41.33 - $74.26 $373,788 - $671,607
-9,044 Reduced 1.75%
507,396 $21.4 Million
Q1 2024

May 06, 2024

SELL
$56.27 - $73.77 $58,408 - $76,573
-1,038 Reduced 0.2%
516,440 $35.7 Million
Q4 2023

Feb 12, 2024

SELL
$59.06 - $75.72 $478,149 - $613,029
-8,096 Reduced 1.54%
517,478 $38.3 Million
Q3 2023

Nov 08, 2023

BUY
$65.94 - $99.04 $49,982 - $75,072
758 Added 0.14%
525,574 $35.9 Million
Q2 2023

Aug 14, 2023

SELL
$62.68 - $95.05 $425,534 - $645,294
-6,789 Reduced 1.28%
524,816 $49.3 Million
Q1 2023

May 11, 2023

SELL
$47.19 - $70.77 $48,464 - $72,680
-1,027 Reduced 0.19%
531,605 $36 Million
Q4 2022

Feb 08, 2023

SELL
$30.35 - $53.15 $122,856 - $215,151
-4,048 Reduced 0.75%
532,632 $26.4 Million
Q3 2022

Nov 09, 2022

SELL
$31.97 - $49.37 $68,639 - $105,997
-2,147 Reduced 0.4%
536,680 $17.4 Million
Q2 2022

Aug 10, 2022

BUY
$35.61 - $76.23 $670,393 - $1.44 Million
18,826 Added 3.62%
538,827 $21.2 Million
Q1 2022

May 12, 2022

BUY
$57.56 - $82.54 $24.6 Million - $35.3 Million
428,049 Added 465.51%
520,001 $36.4 Million
Q4 2021

Feb 10, 2022

BUY
$72.5 - $100.68 $159,355 - $221,294
2,198 Added 2.45%
91,952 $7.16 Million
Q3 2021

Nov 12, 2021

BUY
$90.24 - $124.05 $69,394 - $95,394
769 Added 0.86%
89,754 $8.57 Million
Q2 2021

Aug 06, 2021

BUY
$93.66 - $139.27 $155,569 - $231,327
1,661 Added 1.9%
88,985 $11.1 Million
Q1 2021

May 10, 2021

SELL
$116.57 - $155.01 $3.38 Million - $4.5 Million
-29,015 Reduced 24.94%
87,324 $11.5 Million
Q4 2020

Feb 10, 2021

SELL
$99.61 - $142.12 $16 Million - $22.9 Million
-160,812 Reduced 58.02%
116,339 $15.4 Million
Q3 2020

Nov 13, 2020

SELL
$72.92 - $102.01 $23,115 - $32,337
-317 Reduced 0.11%
277,151 $28.3 Million
Q2 2020

Aug 10, 2020

SELL
$55.75 - $92.75 $188,044 - $312,845
-3,373 Reduced 1.2%
277,468 $24.1 Million
Q1 2020

May 21, 2020

BUY
$37.9 - $104.44 $1.81 Million - $5 Million
47,830 Added 20.53%
280,841 $16.3 Million
Q4 2019

Feb 14, 2020

SELL
$77.66 - $99.74 $471,784 - $605,920
-6,075 Reduced 2.54%
233,011 $21.5 Million
Q3 2019

Nov 12, 2019

SELL
$90.37 - $122.49 $227,732 - $308,674
-2,520 Reduced 1.04%
239,086 $21.6 Million
Q2 2019

Aug 13, 2019

SELL
$89.51 - $118.04 $512,713 - $676,133
-5,728 Reduced 2.32%
241,606 $28.5 Million
Q1 2019

May 15, 2019

BUY
$61.98 - $96.5 $483,567 - $752,893
7,802 Added 3.26%
247,334 $21.4 Million
Q4 2018

Feb 14, 2019

SELL
$56.04 - $82.66 $34,072 - $50,257
-608 Reduced 0.25%
239,532 $15.1 Million
Q3 2018

Nov 09, 2018

SELL
$48.29 - $80.6 $601,307 - $1 Million
-12,452 Reduced 4.93%
240,140 $19 Million
Q2 2018

Aug 14, 2018

SELL
$37.84 - $69.96 $15,136 - $27,983
-400 Reduced 0.16%
252,592 $15.1 Million
Q1 2018

May 15, 2018

SELL
$39.82 - $57.53 $34,285 - $49,533
-861 Reduced 0.34%
252,992 $10.2 Million
Q4 2017

Feb 14, 2018

SELL
$46.49 - $60.51 $1.49 Million - $1.94 Million
-32,049 Reduced 11.21%
253,853 $13.3 Million
Q3 2017

Nov 14, 2017

BUY
$37.05 - $47.12 $78,508 - $99,847
2,119 Added 0.75%
285,902 $13.5 Million
Q2 2017

Aug 14, 2017

BUY
N/A
283,783
283,783 $10 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.77B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.